Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
12.5.
2022

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.

  • The Board and the Chief Executive Officer were discharged from liability.

  • The Board shall consist until the next AGM of five ordinary members without deputies.

  • Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist and Steve Jordan.

Magnus Gustafsson was elected new Board member.

Tiedotteet
27.4.
2022
  • Net sales totaled SEK 32,574 (15,723) thousand, with a growth rate of 107%. About SEK 10 million relates to the license agreement in 2021 with Selecta Biosciences.
Tiedotteet
21.4.
2022

Genovis 2021 Annual Report is now available in Swedish and English at our website.

To read or download the annual report in Swedish, go to:

https://investor.genovis.com/wp-content/uploads/genovis-ar-2021-sv.pdf

To read or download the annual report in English, go to:

https://investor.genovis.com/wp-content/uploads/genovis-ar-2021-en.pdf

Tiedotteet
6.4.
2022

The shareholders of Genovis AB, corporate identity no 556574-5345, are hereby given notice of the Annual General Meeting on Thursday, May 12, 2022.

Tiedotteet
8.2.
2022
October - December 2021    
  • Net sales rose by 112% to SEK 42,060 (19,850) thousand. About SEK 20 million relates to licensing agreements with Selecta Bioscience.
Tiedotteet
12.11.
2021
July - September 2021    
  • Net sales rose by 10% to SEK 15,699 (14,216) thousand.
Tiedotteet
2.11.
2021

Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – a deal that clearly validates the huge potential in the company and its SmartEnzymes. We have hiked our fair value range and argue that the stock is very attractive for the long-term investor thanks to significant optionality on the upside.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Tiedotteet
21.10.
2021

Under the agreement Genovis grants Selecta exclusive license to develop and promote a proprietary IgG protease, Xork™, as a potential pre-treatment prior to the administration of gene therapy and for autoimmune diseases. 

Under the terms of the license:
  • Genovis will receive USD 6 million in upfront and early preclinical milestone payments and is eligible for up to USD 598 million in development, regulatory and sales milestone payments. Additionally, Genovis will receive double digit royalties on sales.

Tiedotteet
6.10.
2021

Genovis has hired Magnus Långberg as the new CFO of the Group; he will begin in January 2022.

Magnus Långberg has over 20 years of experience from a variety of positions within finance and management at international life science companies. He will be joining Genovis from his most recent position at Hemocue AB. Before that he worked at companies such as QPharma and BD Medical.

Tiedotteet
12.8.
2021
Second quarter 2021    
  • Net sales rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects.
  • Gross profit rose by 32% to SEK 17,365 (13,146) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,793 (loss: 38) thousand.
  • Operating profit improved by SEK 2,641 thousand and totaled SEK 1,350 (loss: 1,291) thousand.
  • Comprehensive income for the period improved by SEK 4,156 thousand and totaled SEK 1,033 (loss: 3,123) thousand.
  • Comprehensive income per share, basic and diluted,

Genovis AB